<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="therapies. Based on the existence of common patho-physiological features linking" exact="epilepsy" post="to migraine [ 8], it has been recently postulated"/>
 <result pre="on the existence of common patho-physiological features linking epilepsy to" exact="migraine" post="[ 8], it has been recently postulated that the"/>
 <result pre="glutamate receptors may play a role in the treatment of" exact="migraine" post="[ 9]. In fact, glutamate receptors have been localized"/>
 <result pre="fact, glutamate receptors have been localized in areas related to" exact="migraine" post="patho-physiology, including the trigeminal ganglion, trigeminal nucleus caudalis and"/>
 <result pre="and glutamate receptor antagonists proved effective in animal models of" exact="migraine" post="(reviewed in [ 9]), which encouraged a number of"/>
 <result pre="studies with mGluR5, AMPA and/or kainate receptor antagonists in acute" exact="migraine" post="[ 13– 15]. Within the framework of AEDs and"/>
 <result pre="calcitonin gene-related peptide (CGRP, a peptide neurotransmitter most important in" exact="migraine" post="pathophysiology [ 16]), from acute rat brainstem explants. To"/>
 <result pre="well with the oral administration at the onset of a" exact="migraine" post="attack. The therapeutic area of migraine treatment has recently"/>
 <result pre="the onset of a migraine attack. The therapeutic area of" exact="migraine" post="treatment has recently undergone a fast growth, because of"/>
 <result pre="highly effective and well tolerated, they all are approved for" exact="migraine" post="prevention, meaning that the frequency of migraine attacks in"/>
 <result pre="are approved for migraine prevention, meaning that the frequency of" exact="migraine" post="attacks in patients treated with anti-CGRP antibodies is significantly"/>
 <result pre="but not abolished [ 26]. Thus, the effective treatment of" exact="migraine" post="attacks remains a partially unmet need, which warrants studies"/>
 <result pre="AMPA-receptor antagonist that reduces seizure activity in rodent models of" exact="epilepsy" post="Epilepsia 2011 52 1331 1340 10.1111/j.1528-1167.2011.03109.x 21635236 3. French"/>
 <result pre="K VanDenBrink A Glutamate receptor antagonists in the management of" exact="migraine" post="Drugs 2014 74 1165 1176 10.1007/s40265-014-0262-0 25030431 10. Kai-Kai"/>
 <result pre="a novel AMPA/GluR5 antagonist, is efficacious and well-tolerated in acute" exact="migraine" post="Cephalalgia 2004 24 596 602 10.1111/j.1468-2982.2004.00723.x 15196302 14. Gomez-Mancilla"/>
 <result pre="novel AMPA receptor antagonist BGG492 for the treatment of acute" exact="migraine" post="attacks Cephalalgia 2014 34 103 113 10.1177/0333102413499648 23963355 15."/>
 <result pre="migraine: a proof of concept study of ADX10059 in acute" exact="migraine" post="treatment Cephalalgia 2009 29 Suppl 1 7 16. Villalón"/>
 <result pre="Olesen J The role of CGRP in the pathophysiology of" exact="migraine" post="and efficacy of CGRP receptor antagonists as acute antimigraine"/>
 <result pre="AR Goadsby PJ Anti-CGRP monoclonal antibodies: the next era of" exact="migraine" post="prevention? Curr Treat Options Neurol 2017 19 27 10.1007/s11940-017-0463-4"/>
</results>
